

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1.(currently amended) A pharmaceutical liposomal formulation for photodynamic therapy, which can be safely freeze-dried and reconstituted, comprising a lipid bilayer which consists substantially of synthetic phospholipids, a monosaccharide, and a therapeutically effective amount of a non-polar di- or tetrahydro porphyrin derivative. selected from the group consisting of chlorin, bacteriochlorin, porphyrinogen and iso-bacteriochlorin.
2. (currently amended) The liposomal formulation according to claim 1, wherein said synthetic phospholipids are selected from the group consisting of dipalmitoyl phosphatidyl choline, dipalmitoyl phosphatidyl glycerol, poly(ethylene glycol)-linked phospholipids and combinations of these ~~three~~ materials.
- 3.(cancelled)
- 4.(cancelled)
- 5.(cancelled)
- 6.(currently amended) The liposomal formulation according to claim [5] 1 wherein said monosaccharide is selected from the group consisting of glucose and fructose.
- 7.(cancelled)
- 8.(currently amended) The liposomal formulation according to claim [5] 1 wherein the concentration ratio of monosaccharide to phospholipid is between 1:2 and 1:12.
- 9.(cancelled)
- 10.(currently amended) The liposomal formulation according to claim [5] 1, reconstituted with an aqueous fluid for pharmaceutical administration.
- 11.(original) The liposomal formulation according to claim 1 wherein the therapeutically effective concentration of the photosensitizer is from 0.0001 to 0.15 percent w/v.

12.(cancelled)

13.(original) The liposomal formulation according to claim 1 further comprising a component selected from the group consisting of butylated hydroxytoluene, ascorbic palmitate, and combinations of these two.

14.(cancelled)

15.(cancelled)

16.(cancelled)